Bengaluru-based companies Vipragen and Zumutor have announced a strategic partnership to set up an end-to-end Biologics contract research organisation (CRO) platform to support discovery, clone to pre-clinical development of biologics/biosimilars.

This partnership will address ‘all things biology’ from biologics discovery and development to Investigational New Drug Application (IND) submissions. This will address the needs of research programmes from institutions and emerging to mid-size biotech companies. These programmes focus on biologics for cancer biology, metabolic diseases, pain and inflammation, and neuroscience.

Through this collaboration, Vipragen and Zumutor aim to expedite R&D progression, ensure high-quality data, and reduce costs by bringing global research programmes to progress into quicker commercialisation stage.

This strategic alliance is expected to enhance the capabilities of both organisations and significantly contribute to the innovators to take their programmes to next level. 

"We are confident that this strategic collaboration will enhance our capabilities and contribute significantly in advancing innovation in the biologics space. Our partnership promises to deliver end to end solutions and drive research excellence, benefiting clients and partners worldwide," said Dr Chandrasekaran, Chairman and MD of Vipragen.

"This partnership with Vipragen marks a significant milestone for us. By combining our innovative antibody discovery platform with Vipragen's extensive pre-clinical capabilities, we aim to provide unmatched value to our clients and substantial value to both the Companies. Together, we will drive the next generation of biologics research for innovators," said Kavitha Iyer Rodrigues, Founder & CEO of Zumutor.